Posted by Michael Wonder on 02 Mar 2023
Verrica Pharmaceuticals announces FDA acceptance of filing of resubmitted NDA for VP-102 for the treatment of molluscum contagiosum
27 February 2023 - Assigns PDUFA goal date of 23 July 2023.
Verrica Pharmaceuticals today announced that the US FDA accepted for filing the Company’s resubmitted new drug application for VP-102 for the treatment of molluscum contagiosum.
